Hello sir, i am interested in entering into biopharma business, currently we are into contract manufacturing of chemical intermediates and fine chemicals, at kolhapur, and now looking forward to expand our business. I would be grateful if we can find consultant cum marketer in the same business.Looking forward for further discussion
+24 Other Responses
I am a research analyst. I am currently working on a project which deals with the biopharmaceutical contract manufacturing organization (cmo) market. The following are the deliverable that need to be addressed.
- cost model for monoclonal antibody manufacturing by a cmo or biopharmaceutical company.
- global mammalian and microbial drug manufacturing capacities.
- capacity of cmos and that of biopharma companies
- capacity of mammalian and microbial cell culture manufacturing by region+22 Other Responses
Our research group in oklahoma state university is developing a new single use bioreactor with some novel features, and we are now in the process of evaluating the potential of commercializing our product. For that reason we are trying to interview some experts in the biopharmaceutical industry and we will appreciate if we can have a short interview with you.
If you would kindly provide us with a phone number and a good time for you to have a short call it will be highly appreciated.
Thank you.+19 Other Responses
Supply Chain Best Practices In Biopharma
I am writing on behalf of a consulting firm that conducts expert interviews in support of industry-wide studies for many of the world's fortune 1000 companies. We help businesses answer questions by engaging with the world’s most relevant experts. So far we have delivered over 1000 studies with input from over 18,000 individuals. We are an authorized zintro partner.
For a current study, we are seeking to speak with experts who can share insights around the impact that potential us tax system changes might have on the bio-pharma manufacturing sector. More specifically, our client assumes that the new trump administration in the us will incur major changes in tax systems (e.G. Corporate tax cut, tax exemption over export products, etc.). We are seeking to understand what would be the key changes, resulting from that, or key impacts over bio-pharma in-house or outsourcing strategy. Please note that we would only consider us- or europe-based experts with recent experience and who can provide shared learnings from one or more of the following companies:
1st priority: j&j, bms, pfizer, abbvie, amgen
2nd priority: roche/genentech, novartis, astrazeneca
please note that we are only interested in your personal point of view and expert insight and are not seeking any confidential information.
We would welcome any referrals to other relevant experts as well.
vlady+9 Other Responses